Monte Rosa Therapeutics to Present at Upcoming Investor and Industry Conferences
30 Maggio 2023 - 10:30PM
Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage
biotechnology company developing novel molecular glue degrader
(MGD)-based medicines, today announced the company is scheduled to
present at the following investor and industry events in June:
- BIO International Healthcare Conference in Boston; panel
entitled “From Serendipity to Rational Design, Redefining the Rules
of Molecular Glue Discovery” on June 5 at 1PM ET in Session Room
208
- Jefferies Healthcare Conference in New York; presentation on
June 8 at 4:30PM ET
Webcasted presentations will be accessible via the “Events &
Presentations” section of the company’s investor site
at https://ir.monterosatx.com/, and an archived version will
be made available for 90 days following the
presentation.About Monte RosaMonte Rosa
Therapeutics is a biotechnology company developing novel molecular
glue degrader (MGD) medicines for patients with serious diseases
such as oncology, autoimmune and inflammatory diseases. MGDs are
small molecule protein degraders that employ the body’s natural
mechanisms to selectively eliminate therapeutically relevant
proteins. The Company’s QuEEN™ (Quantitative and Engineered
Elimination of Neosubstrates) platform enables it to rapidly
identify protein targets and design highly selective degraders by
combining diverse libraries of proprietary MGDs with in-house
proteomics, structural biology, AI/machine learning, and
computational chemistry capabilities. For more information,
visit www.monterosatx.com
Investors
Shai Biran
Monte Rosa Therapeutics
ir@monterosatx.com
Media
Cory Tromblee
Scient Public Relations
media@monterosatx.com
Grafico Azioni Monte Rosa Therapeutics (NASDAQ:GLUE)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Monte Rosa Therapeutics (NASDAQ:GLUE)
Storico
Da Mag 2023 a Mag 2024